Results 171 to 180 of about 472,711 (314)

Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?

Brain : a journal of neurology, 2011
Y. Compta, L. Parkkinen, S. O'sullivan, J. Vandrovcova, J. Holton, C. Collins, T. Lashley, C. Kallis, David R. Williams, Rohan de Silva, A. Lees, T. Révész   +11 more
semanticscholar   +1 more source

Mitochondria and the Actin Cytoskeleton in Neurodegeneration

Cytoskeleton, EarlyView.
ABSTRACT Mitochondrial dysfunction and cytoskeletal disorganization are widely recognized hallmarks of neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS).
Shivani Tuli, Preet Patel, Aneri Shethji, David Gau   +3 more
wiley   +1 more source

Parkinson's Disease Dementia: Synergistic Effects of Alpha-Synuclein, Tau, Beta-Amyloid, and Iron. [PDF]

Front Aging Neurosci, 2021
Han J, Fan Y, Wu P, Huang Z, Li X, Zhao L, Ji Y, Zhu M.   +7 more
europepmc   +1 more source

Commentary: Three questions for the study of traumatic brain injury in animals

The Anatomical Record, EarlyView.
Gregory Hollin
wiley   +1 more source

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

Environmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons, Marc A. Beal, Kerry L. Dearfield, George R. Douglas, Min Gi, B. Bhaskar Gollapudi, Robert H. Heflich, Katsuyoshi Horibata, Michelle Kenyon, Alexandra S. Long, David P. Lovell, Anthony M. Lynch, Meagan B. Myers, Stefan Pfuhler, Alisa Vespa, Andreas Zeller, George E. Johnson, Paul A. White   +17 more
wiley   +1 more source

Temporal Trends in the Epidemiology of Eating Disorders Between 2000 and 2022: A Danish Register Study of Their Incidence and Comorbidities

European Eating Disorders Review, EarlyView.
ABSTRACT Background Eating disorders are debilitating illnesses that often co‐occur with other psychiatric disorders and somatic diseases. Evidence indicates that the incidence of eating disorders has been increasing. We first examine the landscape of EDs over time, including the COVID‐19 period, via assessing the incidence of anorexia nervosa (AN ...
Nadia Micali, Helena L. Davies, Heidi Jeannet Graff, Laust H. Mortensen, Emilie R. Hegelund   +4 more
wiley   +1 more source

Pharmacological effects of gastrodin: Insight into neurological diseases and mechanism in ferroptosis and pyroptosis

Ibrain, Volume 11, Issue 1, Page 74-83, Spring 2025.
Pharmacological effects of gastrodin include prevention and treatment of cognitive decline and reperfusion injuries, anticonvulsion, antiepilepsy, antidepressants, and analgesia, which are related to antiferroptosis and antipyroptosis. Abstract Gastrodin, as an effective monomer of gastrodia elata, plays a significant role in anti‐inflammatory ...
Xue Zheng, Jing Li, Zhao‐Qiong Zhu
wiley   +1 more source

Predicting the Severity of Parkinson's Disease Dementia by Assessing the Neuropsychiatric Symptoms with an SVM Regression Model. [PDF]

Int J Environ Res Public Health, 2021
Byeon H.
europepmc   +1 more source

α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies

, 1998
M. Spillantini, R., Anthony Crowther, R. Jakes, M. Hasegawa, M. Goedert   +5 more
semanticscholar   +1 more source

Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.

Cochrane Database of Systematic Reviews, 2012
M. Rolinski, C. Fox, I. Maidment, R. McShane   +3 more
semanticscholar   +1 more source